At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Early Stage Unresected Non-Small Cell Lung Cancer Treatment Study

Clinical Trial Title: 
Durvalumab vs placebo following stereotactic body radiation therapy in early stage unresected non-small cell lung cancer patients.
Clinical Trial Protocol ID: 
19032002
Clinical Trial Investigator Name: 
Mary Jo Fidler, MD
Clinical Trial Protocol Description: 

The purpose of this study is to find out if a drug called durvalumab will work and be safe for the treatment of patients with stage I/II non-small cell lung cancer (NSCLC) following stereotactic body radiation therapy. Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy, is a treatment for cancer that gives very high doses of radiation, using several beams of different strengths aimed at different angles to precisely target a tumor.

Qualifying participants will receive either durvalumab or a placebo once a month for up to 24 months after completing SBRT. Participants will be randomly assigned to either group (50/50 chance, like the flip of a coin). The study drug or placebo will be given intravenously for about 1 hour. Participants will need to return to the clinic every 4 weeks to receive the treatment. During study visits, participants may have the following procedures: have blood and other radiographic tests (CT/MRI), discuss side effects and general health, review current medications, undergo a physical exam, have an ECG (electrocardiogram, a test to measure the pattern of your heart beats).

The study is expected to last about 6 years.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are at least 18 years of age.
  • Are stage I to II with clinical stage I/II lymph node-negative (T1 to T3N0M0).
  • Have completed SBRT as definitive treatment prior to enrollment in the study.

You will be excluded from the study if any of the following criteria apply to you:

  • Have active or prior documented autoimmune or inflammatory disorders.
  • Have prior exposure to immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-programmed cell death ligand 2 antibodies.
  • Have a history of active primary immunodeficiency or infection.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Lung and Chest Tumors
Contact Email: 
Contact Phone: 
(312) CANCER-1
Contact Name: 
Rush Cancer Center Clinical Trials Office